The World Bank has begun attaching 'reproducibility packages'—containing raw data and analysis code—to all research it publishes, following concerns that findings in social and behavioural sciences are often hard for independent researchers to replicate. The move, underway since 2023 and standard since 2025, follows broader studies this year documenting widespread reproducibility problems across scientific fields.
A Nature retrospective highlights the scientific career of William Thomson, later Lord Kelvin, noting that his contributions extended well beyond the temperature scale that bears his name. The piece surveys his broader body of work in physics and engineering during the 19th century.
Two recent reports—the World Inequality Lab's Global Justice Report and a UN High-Level Expert Group's Beyond GDP recommendations—have reignited debate over whether nations should deprioritize economic growth in favor of other measures of well-being. A commentary argues both reports miss the real issue: whether governments are leaving future generations richer or poorer, not simply how fast economies grow or how well-being is measured.
NASA launched the Nancy Grace Roman Space Telescope on August 30, marking the first space telescope named after a woman. The mission, previously known as WFIRST, will study dark matter, dark energy, and exoplanets, continuing work in the field Roman helped establish as NASA's first chief of astronomy in 1959.
An anonymous researcher alerted the UK Biobank in April to sensitive participant data being sold on Alibaba's Xianyu marketplace, prompting officials to work with UK and Chinese authorities to remove the listing. The biobank then suspended researcher access for nearly five months while investigating the breach and rebuilding its data security infrastructure, with access set to resume this month.
An editorial in Nature argues that prediction markets allowing wagers on the outcomes of clinical trials pose risks to research integrity and public trust in science. It calls for limits on such betting activity to prevent interference with ongoing trials.
Responding to Ming Li's proposal to separate academic 'titles' from resource allocation in Chinese universities, a Nature correspondence argues the reform is unlikely to succeed. The author agrees that suppressed performance indicators tend to resurface under different labels, but contends university administrators benefit from the current metric-based system and thus have little incentive to change it.
A recent catastrophic flood event in Nepal illustrates how multiple climate-related hazards can combine to produce disasters far more severe than any single risk factor would suggest. Nature's commentary uses the event to argue that scientists and policymakers have been underestimating the danger posed by such compound risks.
A commentary published in Nature argues that governance frameworks for AI in healthcare should place patients, not just clinicians or regulators, at the center of decision-making. The piece calls for structures that give patients meaningful input into how AI tools are developed, deployed and monitored in clinical settings.
The authors of a study on histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia have issued a correction after discovering that an H3K4me3 immunoblot in Extended Data Fig. 9e was mistakenly duplicated from the H3K27me3 blot during figure preparation. The correct blot image has been posted in the Supplementary Information, and new scans of all panels from the original source films have been provided, with source films archived on Figshare.
Two children died in separate Chinese gene-editing trials — a boy in a 2025 trial by HuidaGene Therapeutics and a six-year-old girl in March 2024 after treatment developed by researchers at Shanghai Jiao Tong University and Xinhua Hospital. Shanghai Jiao Tong University has launched an investigation into the girl's case and a related study published in Nature, while HuidaGene disclosed the boy's death publicly in August.
Two children reportedly died after receiving gene-editing treatments in separate investigator-initiated trials (IITs) in China, drawing scrutiny to the country's rapid trial pathway. The deaths surfaced just months after Beijing introduced Order 818, a rule effective May 1 that tightens oversight of IITs, including restricting stem-cell and gene therapy trials to top-tier sanjia hospitals.
GoKawiil